FLEBOGAMMA 5% SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

IMMUNOGLOBULIN (HUMAN)

Disponibbli minn:

INSTITUTO GRIFOLS S.A.

Kodiċi ATC:

J06BA02

INN (Isem Internazzjonali):

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASC. ADM.

Dożaġġ:

50MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

IMMUNOGLOBULIN (HUMAN) 50MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

10/50/100/200/400ML

Tip ta 'preskrizzjoni:

Schedule D

Żona terapewtika:

SERUMS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0106267002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2017-08-17

Karatteristiċi tal-prodott

_Page 1 of 28_
PRODUCT MONOGRAPH
FLEBOGAMMA
® 5%
Immune Globulin Intravenous (Human)
Solution for infusion, 50 mg/mL
Passive immunizing agent
Immune sera and immunoglobulins: immunoglobulins, normal human, for
intravascular
administration. ATC code: J06BA02
Manufactured by:
Instituto Grifols, S.A.
Can Guasc, 2 - Parets del Vallès
E-08150 Barcelona
Spain
Imported and Distributed by:
Grifols Canada Ltd.
5060 Spectrum Way
Suite 405
Mississauga, Ontario
L4W 5N5
Date of Approval:
August 17, 2017
Submission Control No: 194291
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
11
DOSAGE AND ADMINISTRATION
.............................................................................
11
OVERDOSAGE
...............................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 13
STORAGE AND STABILITY
.........................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
......................................................................
15
DOSAGE FORMS, COMPOSITION AND PA